| Literature DB >> 24482061 |
Martin Gulliford1, Judith Charlton1, Nawaraj Bhattarai1, Caroline Rudisill2.
Abstract
BACKGROUND: We developed a method to model the cost-effectiveness at different levels of deprivation of an intervention to promote physical activity.Entities:
Keywords: brief intervention; economic evaluation; health inequality; physical activity; primary care; socioeconomic position
Mesh:
Substances:
Year: 2014 PMID: 24482061 PMCID: PMC4245899 DOI: 10.1093/pubmed/fdt132
Source DB: PubMed Journal: J Public Health (Oxf) ISSN: 1741-3842 Impact factor: 2.341
Fig. 1Outline of Markov model. Single conditions: states include diabetes mellitus, coronary heart disease, stroke or colorectal cancer; dual conditions: states include each potential combination of two of these four conditions; triple conditions: states include each potential combination of three of these four conditions; quadruple conditions: state includes all four conditions combined. Individuals in any state may reversibly transition to comorbid depression (not shown) or irreversibly to death. Arrows indicate transitions between states.
Association of deprivation quintile with disease incidence, mortality and depression prevalence in single condition states.
| Population at risk | CPRD | Frequency | Male | 23 784 | 20 109 | 21 388 | 18 315 | 19 671 |
| Female | 25 149 | 21 171 | 22 689 | 18 782 | 19 749 | |||
| Mean age (SD) | CPRD | Mean (SD) years | Male | 51.1 | 51.8 | 51.5 | 50.4 | 49.3 |
| Female | 53.1 | 53.9 | 53.9 | 53.2 | 52.2 | |||
| Physical inactivity (%) | HSE | Age standardized prevalence | Male | 24.2 | 27.0 | 28.7 | 32.4 | 40.7 |
| Female | 31.9 | 31.3 | 33.2 | 36.5 | 43.5 | |||
| Disease incidence | CPRD | Hazard ratio | DM | Reference | 1.16 | 1.29 | 1.49 | 1.76 |
| CHD | Reference | 1.10 | 1.15 | 1.27 | 1.47 | |||
| Stroke | Reference | 1.15 | 1.26 | 1.27 | 1.51 | |||
| Colorectal | Reference | 1.06 | 1.05 | 1.05 | 1.04 | |||
| Mortality | CPRD | Hazard ratio | At risk | Reference | 1.09 | 1.16 | 1.31 | 1.49 |
| DM | Reference | 0.92 | 0.95 | 1.04 | 1.14 | |||
| CHD | Reference | 0.98 | 1.03 | 1.12 | 1.19 | |||
| Stroke | Reference | 1.29 | 1.12 | 1.19 | 1.37 | |||
| Colorectal | Reference | 0.77 | 1.06 | 1.25 | 1.12 | |||
| Depression prevalence | CPRD | Odds ratio | At risk | Reference | 1.15 | 1.22 | 1.44 | 1.86 |
| DM | Reference | 1.20 | 1.33 | 1.43 | 1.83 | |||
| CHD | Reference | 1.34 | 1.33 | 1.50 | 2.01 | |||
| Stroke | Reference | 1.12 | 1.24 | 1.28 | 1.58 | |||
| Colorectal | Reference | 1.01 | 0.83 | 1.36 | 1.27 | |||
Figures derive from coefficients from Weibull models (incidence and mortality) and logistic model (depression prevalence). CHD, coronary heart disease; colorectal, colorectal cancer; CPRD, Clincal Practice Research Datalink; DM, diabetes mellitus type 2; HSE, Health Survey for England.
Cost-effectiveness of an intervention continued for 5 years with the same intervention effectiveness in each quintile of deprivation.
| Number entering intervention | 48 933 | 41 280 | 44 077 | 37 097 | 39 420 |
| Life years lived without disease (per 1000)a | 54.9 (17.5 to 93.5) | 58.7 (17.6 to 99.6) | 62.0 (19.5 to 105.9) | 69.6 (20.0 to 117.9) | 74.5 (22.8 to 128.0) |
| Life years lived with physical morbidity (per 1000)a | |||||
| Single condition | −43.0 (−78.6 to −8.9) | −45.1 (−81.9 to −8.1) | −47.7 (−86.6 to −9.5) | −52.5 (−93.9 to −9.6) | −54.4 (−101.8 to −9.0) |
| Dual conditions | −4.9 (−10.9 to 0.9) | −6.3 (−13.4 to0.95) | −6.2 (−13.4 to 0.6) | −7.5 (−15.8 to 0.95) | −8.9 (−19.4 to 1.60) |
| Triple conditions | −0.2 (−0.9 to 0.4) | −0.4 (−1.2 to 0.54) | −0.3 (−1.2 to 0.5) | −0.5 (−1.7 to 0.8) | −0.5 (−1.8 to 0.8) |
| Life years lived with depression (per 1000)a | −2.4 (−25.2 to 20.1) | −3.4 (−31.2 to 24.0) | −3.5 (−30.0 to 25.6) | −4.5 (−37.7 to 28.3) | −5.2 (−45.8 to 35.4) |
| Total intervention costs (£ per 1000) | 104 162 (104 144 to 104 179) | 105 929 (105 908 to 105 949) | 100 962 (100 941 to 100 983) | 97 547 (97 524 to 97 570) | 102 777 (102 750 to 102 803) |
| Incremental costs of non-intervention health-care utilization (£ per 1000) | −14 767 (−90 670 to 61 982) | −17 287 (−95 244 to 60 879) | −18 070 (−93 970 to 57 185) | −20 674 (−98 192 to 57 335) | −25 047 (−108 110 to 52 555) |
| Incremental total costs (£ per 1000)a | 89 394 (13 483 to 166 160) | 88 642 (10 680 to 166 791) | 82 892 (7172 to 158 163) | 76 873 (−649 to 77 965) | 77 730 (−5342 to 155 326) |
| Incremental QALYs (discounted 3.5%) (per 1000) | 3.73 (−10.05 to 18.30) | 4.09 (−11.6 to 20.2) | 4.45 (−11.7 to 29.7) | 4.7 (−12.7 to 21.0) | 6.1 (−10.2 to 22.9) |
| Incremental QALYs (discounted 1.5%) (per 1000) | 6.32 (−13.15 to 27.26) | 6.9 (−15.8 to 29.2) | 7.62 (−15.5 to 29.7) | 8.1 (−16.0 to 32.0) | 10.3 (−13.7 to 34.8) |
| Net Health Benefit (QALYs per 1000) | 0.75 (−13.32 to 15.38) | 1.13 (−14.7 to 17.8) | 1.69 (−14.7 to 17.3) | 2.11 (−15.7 to 18.8) | 3.5 (−13.3 to 20.6) |
| Probability cost-effective at £30 000 per QALY (%) | 52.5 | 54.0 | 58.0 | 58.8 | 63.3 |
Figures represent the mean (95% interval) for 2000 simulations, except where indicated.
Fig. 2Cost-effectiveness acceptability curves for each quintile of deprivation. Solid line, most deprived quintile; long dashed line, least deprived quintile.
Cost-effectiveness when intervention effect in most deprived quintile is 20 or 30% smaller than in the least deprived quintile.
| Intervention effects (mean, 95% range) | ||||||
| Diabetes mellitus | 0.966 (0.948 to 0.983) | 0.967 (0.949 to 0.983) | 0.973 (0.960 to 0.987) | 0.974 (0.960 to 0.987) | 0.977 (0.965 to 0.988) | 0.977 (0.966 to 0.988) |
| Coronary heart disease | 0.949 (0.924 to 0.973) | 0.950 (0.927 to 0.975) | 0.960 (0.940 to 0.981) | 0.961 (0.942 to 0.979) | 0.966 (0.948 to 0.983) | 0.966 (0.949 to 0.982) |
| Stroke | 0.968 (0.953 to 0.984) | 0.967 (0.953 to 0.985) | 0.975 (0.964 to 0.987) | 0.976 (0.964 to 0.988) | 0.979 (0.968 to 0.989) | 0.979 (0.968 to 0.989) |
| Colorectal cancer | 0.959 (0.938 to 0.979) | 0.960 (0.940 to 0.980) | 0.969 (0.953 to 0.984) | 0.969 (0.954 to 0.984) | 0.973 (0.959 to 0.986) | 0.973 (0.959 to 0.986) |
| Incremental QALYs | 3.6 (−10.7 to 17.9) | 8.9 (−11.9 to 21.7) | 4.4 (−12.6 to 21.5) | |||
| Incremental costs | 89 053 (12 328 to 164 492) | 83 127 (2922 to 162 538) | 83 767 (3219 to 162 945) | |||
| Net Health Benefits | 0.60 (−13.8 to 15.4) | 1.93 (−15.5 to 19.4) | 1.60 (−15.5 to 19.4) | |||
| Probability cost-effective | 52.9 | 57.3 | 55.9 | |||
Figures represent the mean (95% interval) for 2000 simulations, except where indicated. QALYs costs and net health benefits are per 1000 participants.